The Unique Physicochemical Properties of 2.5% Injectable Polyacrylamide Hydrogel (iPAAG) in Joint Lameness Treatment
Introduction The management of osteoarthritis (OA) in equine patients has seen significant advancements with the introduction of 2.5% injectable Polyacrylamide Hydrogel (iPAAG), commercially known as Arthramid®. This short article explores…
The concurrent use of 2.5% polyacrylamide hydrogel and betamethasone esters for intra-articular injection is well tolerated in 10 healthy horses
The Journal of the American Veterinary Medical Association (JAVMA) has recently published a study looking at the safety and tolerability of concurrent use of Arthramid and betamethasone. This research was…
Webinar: Palmar Foot Pain | Advances and Updates in Equine Podiatry
ArthramidVet hosted this discussion with Dr Andrew Watts and Dr Tracy Turner, experts in equine foot health. Our Panelists Dr Andrew Watts (AU): Graduating from University of Queensland in…
Dr Lisa Fortier Seminar | Intra-Articular Approaches to Osteoarthritis
ArthramidVet® and the NZVA offered an exclusive opportunity to hear from the esteemed Dr Lisa Fortier who, alongside Dr Jason Lowe, discussed Intra-Articular Approaches to Osteoarthritis, a general topic that…
Histologic and cytologic changes in normal equine joints after injection with 2.5% iPAAG hydrogel reveal low-level macrophage-driven foreign body response
The prestigious American Veterinary Medicine Association has published another 2.5% iPAAG (ArthramidVet®) study conducted by IMS Vet Directors Dr Jason Lowe and Dr Leigh de Clifford, in keeping with our…
What is a ‘joint-flare’ and can it happen with 2.5% iPAAG (ArthramidVet®)?
Intraarticular injections in horses are beneficial for managing various musculoskeletal conditions, but they do come with associated risks and should be performed by a suitably qualified and experienced veterinarian. Furthermore,…
New and Upcoming Advances in Equine Orthopedics
Updates on 2.5% iPAAG (Polyacrylamide Hydrogel) In our latest webinar, a number of expert practitioners discussed the latest findings of the use of 2.5% iPAAG (ArthramidVet) and upcoming advances. EquiManagement…
Recommendations and Safety of repeat dosing with 2.5% iPAAG ArthramidVet®
Introduction ArthramidVet® is a novel treatment and represents a paradigm shift in how veterinarians and owners think about treating lameness in horses. ArthramidVet® can be used in any joint that…
Understanding Equine Arthritis: An Owners Guide to Treatment and Ethical Considerations
Navigating the Treatment Pyramid, Orthobiologics, and the Nutraceutical Conundrum Introduction Equine arthritis is a prevalent and concerning health issue that affects horses worldwide. It not only poses welfare challenges…
Dr Florent David presentation on 2.5% PAAG Arthramid Vet
View On Demand. VetFest Marketplace – A dedicated Industry Week for the Veterinary Profession View this 40 minute video presentation as Dr Florent David (DVM, MS, Dipl. ACVS & ECVS,…
Published Clinical Trial on the Efficacy of 2.5% PAAG Arthramid® Vet
This article is written for veterinarians, owners and trainers to summarise the major findings from a published study used for the listing of Arthramid Vet as a registered veterinary medicine in New Zealand and Australia. The…
Should veterinarians combine the use of 2.5% PAAG and Corticosteroids
By Dr Jason Lowe, Veterinarian. Treatments in horses due to osteoarthritis traditionally include rest, controlled exercise, corrective shoeing, nutraceuticals (including glucosamine, epiitalis, hyaluronic acid, and PSGAG’s), non-steroidal anti-inflammatory drugs (NSAID’s),…
